'Gas station heroin' is technically illegal and widely available. Here are the facts
WASHINGTON (AP) — Health officials want you to think twice before buying one of those brightly colored little bottles often sold at gas stations, convenience stores and smoke shops.
Sometimes called 'gas station heroin,' the products are usually marketed as energy shots or cognitive supplements but actually contain tianeptine, an unapproved drug that can be addictive and carries risks of serious side effects.
U.S. poison control centers have reported a steady rise in calls linked to the drug for more than a decade. And last month the Food and Drug Administration sent a warning to health professionals about 'the magnitude of the underlying danger or these products.'
Here's what to know about gas station heroin.
How are these products sold in the U.S.?
Tianeptine is approved in a number foreign countries as an antidepressant, usually as a low-dose pill taken three times a day. But it has never been approved by the FDA for any medical condition in the U.S.
Additionally, the drug cannot legally be added to foods and beverages or sold as a dietary supplement — something the FDA has repeatedly warned U.S. companies about.
Still, under-the-radar firms sell tianeptine in various formulas, often with brand names like Zaza, Tianaa, Pegasus and TD Red. Although that is technically illegal, the FDA does not preapprove ingredients added to supplements and beverages.
'It's kind of this grey area of consumer products, or supplements, where the contents are not regulated or tested the way they would be with a medication,' said Dr. Diane Calello of the New Jersey Poison Information and Education System.
Last year, Calello and her colleagues published a study documenting a cluster of emergency calls in New Jersey tied to a flavored elixir called Neptune's Fix. People experienced distress, rapid heartbeat, low blood pressure and seizures after drinking it. More than a dozen of the 20 patients had to be admitted for intensive care.
Why use these products?
Many tianeptine products claim— without evidence or FDA approval— to help users treat medical conditions, including addiction, pain and depression.
In 2018, the FDA issued a warning letter to the maker of a product called Tianna, which claimed to provide 'an unparalleled solution to cravings for opiates.'
While tianeptine is not an opioid, the drug binds to some of the same receptors in the brain, which can temporarily produce effects akin to oxycodone and other opioids. Tianeptine also carries some of the same physiological risks of opioids, including the potential to dangerously depress breathing.
'That's what tends to get people into trouble,' said Dr. Hannah Hays of Nationwide Children's Hospital in Columbus, Ohio. 'They use it for opioid-like effects or to self-treat opioid withdrawal and that can lead to slow breathing and problems like that.'
People dealing with opioid addiction, pain, depression, anxiety and other conditions should see a health professional to get a prescription for FDA-approved treatments, Hays said.
Is tianeptine use going up?
Experts aren't sure but national figures show a big rise in emergency calls involving the drug.
Calls to poison control centers increased 525% between 2018 and 2023, according to a data analysis published earlier this year. In about 40% of cases, the person had to seek medical care, with more than half of them needing critical care.
One explanation for the rise in calls is simply that more Americans are using the products.
But experts also say that the products are triggering more emergencies as they become more potent and dangerous. And the researchers in New Jersey who analyzed Neptune's Fix found that the liquid also contained synthetic cannabis and other drugs.
'You never quite know what's in that bottle,' Calello said. 'It's important for people to know that even if they have used a product before, they could get a bottle that contains something very different from what they're looking for.'
Are there policies that could reduce tianeptine use?
Tianeptine is not included in the federal Controlled Substances Act, which bans or restricts drugs that have no medical use or have a high potential for abuse, such as heroin, LSD and PCP. But about a dozen states have passed laws prohibiting or restricting tianeptine, including Alabama, Georgia, Michigan, Minnesota, Ohio and Tennessee.
In some cases, those laws have led to more cases of withdrawal among users of tianeptine, which can be chemically addictive. But state data also shows some success in reducing harm tied to the drug.
Until recently, Alabama had the highest rate of tianeptine-related calls in the southern U.S., which increased more than 1,400% between 2018 to 2021. But after the state restricted tianeptine in 2021 calls began modestly decreasing while calls across other southern states continued to climb.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
NHS faces paying more for US drugs to avoid future Trump tariffs
Britain faces paying more for US drugs as part of a deal to avoid future tariffs from Donald Trump. The NHS will review drug pricing to take into account the 'concerns of the president', according to documents released after a trade agreement was signed earlier this year. White House sources said it expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of corporate America. A Westminster source said: 'There's an understanding that we would look at the drug pricing issue in the concerns of the president.' The disclosure is likely to increase concerns about American interference in the British health service, which has long been regarded as a flashpoint in trade talks. It comes after Rachel Reeves announced a record £29 billion investment in the NHS in last week's spending review. The Chancellor's plans will drive spending on the health service up towards 50 per cent of all taxpayer expenditure by the mid-2030s, according to economists at the Resolution Foundation. The Telegraph has also learnt that under the terms of the trade deal with America, the UK has agreed to take fewer Chinese drugs, in a clause similar to the 'veto' given to Mr Trump over Chinese investment in Britain. The White House has asked the UK for assurances that steel and pharmaceutical products exported to the US do not originate in China, amid fears the deal could be used to 'circumvent' Mr Trump's punishing tariffs on Beijing. Mr Trump is enraged by how much more America pays for drugs compared with other countries and considers it to be the same issue as he has raised on defence spending. Just as the US president has heaped pressure on European nations to increase the GDP share they allocate to defence, he thinks they should spend more on drug development. An industry source said: 'The way we've been thinking about it and many in the administration have been thinking about it, it's more like the model in Nato, where countries contribute some share of their GDP.' Britain and the US 'intend to promptly negotiate significantly preferential treatment outcomes on pharmaceuticals and pharmaceutical ingredients', the trade deal reads. Pharmaceutical companies are also pushing for reductions in the revenue sales rebates they pay to the NHS under the voluntary scheme for branded medicines pricing, access and growth (VPAG) – a mechanism that the UK uses to make sure the NHS does not overpay. Last week, Albert Bourla, Pfizer's chief executive, said non-US countries were 'free-riding' and called for a US government-led push to make other nations increase their proportionate spend on innovative medicines. He said White House officials were discussing drug prices in trade negotiations with other countries. 'We represent in UK 0.3pc of their GDP per capita. That's how much they spend on medicine. So yes, they can increase prices,' Mr Bourla said. Industry sources said there was no indication yet on what the White House would consider to be a fair level of spending. Whatever the benchmark, Britain will face one of the biggest step-ups. UK expenditure on new innovative medicines is just 0.28pc of its GDP, roughly a third of America's proportionate spending of 0.78pc of its GDP. Even among other G7 nations, the UK is an anomaly. Germany spends 0.4pc of its GDP while Italy spends 0.5pc. Most large pharmaceutical companies generate between half and three quarters of their profits in the US, despite the fact that America typically makes up less than a fifth of their sales. This is because drug prices outside of the US can cost as little as 30pc of what Americans pay. Yet, pharmaceutical companies rely on higher US prices to fund drug research and development, which the rest of the world benefits from. A month ago, Mr Trump signed an executive order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients', which hit out at 'global freeloading' on drug pricing. It stated that 'Americans should not be forced to subsidise low-cost prescription drugs and biologics in other developed countries, and face overcharges for the same products in the United States' and ordered his commerce secretary to 'consider all necessary action regarding the export of pharmaceutical drugs or precursor material that may be fuelling the global price discrimination'. Trung Huynh, the head of pharma analysis at UBS, said: 'The crux of this issue is Trump thinks that the US is subsidising the rest of the world with drug prices. 'The president has said he wants to equalise pricing between the US and ex-US. And the way he wants to do it is not necessarily to bring down US prices all the way to where ex-US prices are, but he wants to use trade and tariffs as a pressure point to get countries to increase their prices. 'If he can offset some of the price by increasing prices higher ex-US, then the prices in America don't have to go down so much.' Mr Huynh added: 'It's going to be very hard for him to do. Because [in the UK deal] it hinges on the NHS, which we know has got zero money.' Under VPAG, pharmaceutical companies hand back at least 23pc of their revenue from sales of branded medicines back to the NHS, worth £3bn in the past financial year. The industry is pushing for this clawback to be cut to 10pc, which would mean the NHS would have to spend around 1.54bn more on the same medicines on an annual basis. The Government has already committed to reviewing the scheme, a decision which is understood to pre-date US trade negotiations. A government spokesman said: 'This Government is clear that we will only ever sign trade agreements that align with the UK's national interests and to suggest otherwise would be misleading. 'The UK has well-established and effective mechanisms for managing the costs of medicines and has clear processes in place to mitigate risks to supply.'


New York Times
an hour ago
- New York Times
Norma Swenson, an Author of ‘Our Bodies, Ourselves,' Dies at 93
Norma Swenson was working to educate women about childbirth, championing their right to have a say about how they delivered their babies, when she met the members of the collective that had put out the first rough version of what would become the feminist health classic 'Our Bodies, Ourselves.' It was around 1970, and she recalled a few of the women attending a meeting she was holding in Newton, Mass., where she lived. It did not go well. One of them shouted at her, 'You are not a feminist, you'll never be a feminist and you need to go to school!' 'I was stricken,' Ms. Swenson remembered in a StoryCorps interview in 2018. 'But also feeling that maybe she was right. I needed to know more things.' She did, however, know quite a bit about the medical establishment, the paternalistic and condescending behavior of male doctors — in 1960, only 6 percent of incoming medical students were female — and the harmful effect that behavior had on women's health. She had lived it, during the birth of her daughter in 1958. Despite the initial tension — the woman who had berated Ms. Swenson felt her activism was too polite, too old-school — the members of the Boston Women's Health Book Collective, as they called themselves, invited Ms. Swenson to join their group. She would go on to help make 'Our Bodies, Ourselves' a global best seller. It was a relationship that lasted for the next half-century. Ms. Swenson died on May 11 at her home in Newton. She was 93. The cause was cancer, her daughter, Sarah Swenson, said. Want all of The Times? Subscribe.


CBS News
an hour ago
- CBS News
Inside SoCal: Learning at Any Age (6/15)
Tuition-free learning to jump-start a new career is the goal of LAUSD's DACE program for adults – at any age. Students share how it's changed their lives for the better. LEARNING AT ANY AGE Sponsored by LAUSD Division of Adult and Career Education Life can get in the way at times, but it's never too late to learn or to change your future. Through LAUSD's DACE program (Division of Adult and Career Education), you can get your GED or learn a brand new skill set in a shorter time frame so you can jumpstart your new career. Tuition-free classes are a key component of this program, as are the diverse classes available – healthcare, tech, trades, and more. It's also designed for people juggling work, family, and everything else. They have campuses all over LA, as well as online options. Learn more at It's never too late to pursue your dreams.